Department of Pharmacy Practice, Jyothishmathi Institute of Pharmaceutical Sciences, Karimnagar, Telangana, India.
Received on 18 May 2024; revised on 28 June 2024; accepted on 01 July 2024
The current treatment regiment for DS-TB(Drug Resistant Tuberculosis) was defined by 1980's since then the emergency of HIV and escalation of Drug sensitive (DS-TB)forms of TB have presented new challenges.To face these challenges, achieve goals like shortening DS -TB treatment improving DR-TB treatment and making combined TB -HIV therapy easier. A range of new drugs and treatment strategies are currently being elevated. Phase 2B and 3 clinical trials are ongoing to access combinations involving in high dose rifamycins, 8methoxyquinolines,diarylquinolines and nitroimidazoles. The new drugs advantages will contribute towards the achievement of a new treatment regimen in future. Tuberculosis according to WHO: TB is a bacterial infection that mainly affects the lungs and it is caused by the bacteria mycobacterium tuberculosis.
Tuberculosis; Pretomanid; Delamaind; Bedaquiline
Preview Article PDF
Kamatam Meghana, Dollu Rakshitha, Vurugonda sreshta and Kaleru Purnachander. Revolutionizing TB treatment: Breakthrough antibiotics for a healthier future A comprehensive review. International Journal of Science and Research Archive, 2024, 12(02), 157–161. Article DOI: https://doi.org/10.30574/ijsra.2024.12.2.1175






